Johnson & Johnson COVID-19 vaccine authorized for emergency use in India

  • India has granted the emergency use authorization for COVID-19 shot developed by Johnson & Johnson (NYSE:JNJ), the country's health minister Mansukh Mandaviya said.
  • The approval was based on the topline data from the Phase 3 ENSEMBLE clinical trial. The company has inked a supply agreement with local vaccine maker Biological E Ltd. for deliveries. However, the timeline of supplies remains unclear.
  • "While we look forward to meeting our delivery commitments it is premature for us to speculate on the timing of our vaccine deliveries," Reuters quoted the U.S.-based J&J as saying.
  • J&J's single-dose shot is the fifth COVID-19 vaccine to win regulatory authorization in India after those from AstraZeneca (NASDAQ:AZN), Bharat Biotech, Gamaleya Institute of Russia, and Moderna (NASDAQ:MRNA).
  • India has recorded the second-highest number of COVID-19 infections globally, according to data from Johns Hopkins University.
  • The number of COVID-related deaths is the third highest in the world, but the country has fully inoculated only about 8% of its total population.

    For this year the company, located in New Brunswick revenue will be around 94.44 billion USD. This is according to the average of the analysts' estimates. This is rather significant more than 2021's revenue of 82.58 billion USD.

    Historical revenues and results Johnson & Johnson plus estimates 2021

    beurskoers

    The analysts expect for 2021 a net profit of 25.79 billion USD. The majority of the analysts expects for this year a profit per share of 9.67 USD. With this the price/earnings-ratio is 18.39.

    Per share the analysts expect a dividend of 4.17 USD per share. The dividend yield is then 2.34 percent. The average dividend yield of the health care companies is a low 1.25 percent.

    Latest estimates around 177 USD

    The latest 3 recommendations for the health care company were provided by Credit Suisse , ABN AMRO and KBC Securities.

    Johnson & Johnson 's market capitalization is based on the number of outstanding shares around 468.17 billion USD. 23

    Historical stock prices Johnson & Johnson period 2007-2021

    stock johnson&johnson

    At 19.28 the stock trades 0.39 percent higher at 177.84 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.